Mesoblast LtdNASDAQ:MESO
- LAST PRICE6.3800
- TODAY'S CHANGE (%)-0.4000 (-5.8997%)
- Bid / Lots6.3400/ 4
- Ask / Lots6.4100/ 1
- Open / Previous Close6.5000 / 6.7800
- Day Range
- 52 Week Range
- Volume42,302
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MESO |
|---|---|---|
| 09:32 ET | 5468 | 6.5 |
| 09:36 ET | 3374 | 6.45 |
| 09:38 ET | 3920 | 6.46 |
| 09:39 ET | 350 | 6.46 |
| 09:41 ET | 7241 | 6.46 |
| 09:43 ET | 100 | 6.46 |
| 09:45 ET | 400 | 6.43 |
| 09:48 ET | 2384 | 6.455 |
| 09:52 ET | 450 | 6.38 |
Yesterday
Mesoblast to File Biologics License Application for Ryoncil(R) FDA Approval Next Week, from 1:55AM ET on Monday Jul 01, 2024 by Dow Jones
1:55AM ET on Monday Jul 01, 2024 by Dow Jones
Jun 2, 2024
Mesoblast Corporate Presentation at Investor Conference, from 8:23PM ET on Sunday Jun 02, 2024 by Dow Jones
8:23PM ET on Sunday Jun 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mesoblast Ltd | 760.3M | -4.4x | --- |
SS Innovations International Inc | 725.6M | -31.0x | --- |
Perspective Therapeutics Inc | 754.6M | -6.8x | --- |
Stoke Therapeutics Inc | 722.9M | -5.7x | --- |
89Bio Inc | 763.5M | -3.8x | --- |
Nuvation Bio Inc | 781.1M | -9.7x | --- |
Company Information
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
Contact Information
- Headquarters
- L 38 55 Collins StMELBOURNE, VIC, Australia 3000
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Jane Bell
- Chief Executive Officer, Executive Director
- Silviu Itescu
- Non-Executive Independent Vice Chairman of the Board
- William Burns
- Interim Chief Financial Officer
- Andrew Chaponnel
- Chief Operating Officer
- Dagmar Rosa-Bjorkeson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $760.3M |
|---|---|
Revenue (TTM) | $7.5M |
Shares Outstanding | 114.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.48 |
EPS | $-1.44 |
Book Value | $12.34 |
P/E Ratio | -4.4x |
Price/Sales (TTM) | 101.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -735.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
